| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5690704 | Gynecologic Oncology | 2016 | 6 Pages |
Abstract
Patients' preferences for bevacizumab in the adjuvant treatment of ovarian cancer depend primarily on drug costs. Our results suggest that the current cost of bevacizumab is sufficiently high that the majority of ovarian cancer patients are not willing to pay to accept a small increase in progression-free survival.
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Jung-Yun Lee, Kyunghoon Kim, Yun Shin Lee, Hyo Young Kim, Eun Ji Nam, Sunghoon Kim, Sang Wun Kim, Jae Weon Kim, Young Tae Kim,